Investors

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

Date Title and Summary  
Toggle Summary OvaScience and Millendo Therapeutics Provide Update on Merger Agreement and Financing
– New Commitment by Great Point Partners Brings Proceeds of Transactions to $87 Million – – Current OvaScience Shareholders to Benefit from Improved Exchange Ratio – WALTHAM, Mass. & ANN ARBOR, Mich. --(BUSINESS WIRE)--Nov. 1, 2018-- OvaScience SM (Nasdaq:OVAS) and privately-held Millendo
View HTML
Toggle Summary OvaScience Reports Second Quarter 2018 Financial Results and Provides Strategic Alternatives Update
WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 9, 2018-- OvaScience SM (Nasdaq:OVAS), a company focused on developing novel treatments for women and couples struggling with infertility, today reported financial results for the second quarter ended June 30, 2018 and provided an update on its review of
View HTML
Toggle Summary OvaScience and Millendo Therapeutics Announce Merger to Create Leading Rare Endocrine Disease Company
– Transaction to Advance Millendo’s Compelling Pipeline of Late-Stage Programs for Orphan Endocrine Diseases Including Prader-Willi Syndrome – – Companies to Host Conference Call to Discuss Transaction at 8:30 a.m. ET – WALTHAM, Mass. & ANN ARBOR, Mich. --(BUSINESS WIRE)--Aug.
View HTML
Toggle Summary OvaScience Reports First Quarter 2018 Financial Results and Provides Business Update
WALTHAM, Mass. --(BUSINESS WIRE)--May 3, 2018-- OvaScience SM (Nasdaq:OVAS), a company focused on the development of new treatment options for women and couples struggling with infertility, today reported financial results for the first quarter ended March 31, 2018 and provided a business update.
View HTML
Toggle Summary OvaScience Reports Fourth Quarter and Year-End 2017 Financial Results
– Initial Data from First 20 Patients in Phase 1 Clinical Trial of OvaPrime Indicates Safety and Tolerability; Conducting Additional Preclinical Studies to Optimize Proposed Phase 1b/2a Clinical Trial – – Appointed James Lillie, Ph.D. as Chief Scientific Officer to Lead Advancement of OvaTure
View HTML
Toggle Summary OvaScience Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 12, 2018-- OvaScience SM , Inc. (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced the grant of an inducement award to its newly
View HTML
Toggle Summary OvaScience to Host Fourth Quarter and Fiscal Year 2017 Financial Results Conference Call
WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 8, 2018-- OvaScience℠ (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced that it will host a conference call at 4:30 p.m.
View HTML
Toggle Summary OvaScience to Present at the 36th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 4, 2018-- OvaScience℠ (NASDAQ: OVAS), a company focused on the discovery, development and commercialization of new treatment options for women and families struggling with infertility, today announced that Christopher Kroeger , M.D., Chief Executive Officer of
View HTML
Toggle Summary OvaScienceSM Announces Corporate Update
– Reporting Safety Data from First 20 Patients in Phase 1 Study of the OvaPrime SM Treatment; Advancing OvaPrime into Phase 1b/2a Multi-Center Trial – – James Lillie , Ph.D., Joining as Chief Scientific Officer to Lead Ongoing Preclinical Research & Development Efforts – – Improving Financial
View HTML
Toggle Summary OvaScience Reports Third Quarter 2017 Financial Results
– Initial Safety Data from First 20 Patients in OvaPrime℠ Clinical Trial Expected by Year-End – – Granted Exclusive License to IVF Japan Group to Offer the AUGMENT℠ Treatment in Japan – – Conference Call Today at 4:30 p.m. ET – WALTHAM, Mass. --(BUSINESS WIRE)--Nov.
View HTML
Toggle Summary OvaScience to Host Third Quarter 2017 Financial Results Conference Call
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 26, 2017-- OvaScience SM (NASDAQ: OVAS), a fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.m. ET on Thursday, November 2, 2017 to discuss
View HTML
Toggle Summary OvaScience Reports Second Quarter 2017 Financial Results
– Fertilization of Bovine EggPC Cell-Derived Egg in OvaTure Program on Track for Year-End – – Completed Target Enrollment in OvaPrime Clinical Safety Study; Expect to Announce Initial Safety Data in First 20 Patients by Year-End – – Sufficiently Funded to Support Operations into 1Q 2020, Enabling
View HTML
Toggle Summary OvaScience to Host Second Quarter 2017 Financial Results Conference Call
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 27, 2017-- OvaScience SM (NASDAQ: OVAS), a fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.m. ET on Thursday, August 3, 2017 to discuss second
View HTML
Toggle Summary OvaScience Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 21, 2017-- OvaScience℠, Inc. (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the grant of an inducement award to its newly appointed Chief Executive Officer
View HTML
Toggle Summary OvaScience Appoints Christopher Kroeger, M.D., M.B.A., as Chief Executive Officer
– Dr. Kroeger's Combined Business and Medical Experience Ideally Suited to Drive Company’s OvaTure and OvaPrime-Focused Strategy – – Company Restructures Organization to Align with R&D Efforts and Extend Cash Runway into Q1 2020, Enabling Key 2019 Milestones – WALTHAM, Mass. --(BUSINESS WIRE)--Jun.
View HTML
Toggle Summary OvaScience Completes Enrollment of 70 Patients in OvaPrime Clinical Study in Women with Primary Ovarian Insufficiency or Poor Ovarian Response
– Initial Data from First 20 Patients Expected by Year-End 2017 – WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 13, 2017-- OvaScience SM Inc. (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced it has completed
View HTML
Toggle Summary OvaScience Reports First Quarter 2017 Financial Results
–Fertilization of Bovine EggPC Cell-Derived Egg in OvaTure Program on Track for Year-End– –OvaPrime Clinical Trial Progressing Toward Year-End Initial Readout– –Robust Financial Position Supports Corporate Strategy into 1Q19– –Conference Call Today at 4:30 p.m. ET– WALTHAM, Mass.
View HTML
Toggle Summary OvaScience to Host First Quarter 2017 Financial Results Conference Call
WALTHAM, Mass. --(BUSINESS WIRE)--May 2, 2017-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.m.
View HTML
Toggle Summary OvaScience Reports Fourth Quarter and Year-End 2016 Financial Results
OvaTure Program On Track to Successfully Fertilize a Bovine EggPC Cell-Derived Egg 50 Patients Enrolled in OvaPrime Clinical Trial Cash Position Expected to Support Operations into Q12019 Conference Call Today at 4:30 p.m. ET WALTHAM, Mass. --(BUSINESS WIRE)--Mar.
View HTML
Toggle Summary OvaScience to Present at Upcoming Investor Conferences in March
WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 27, 2017-- OvaScience℠ (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that Christophe Couturier, Chief Financial Officer of OvaScience, will present a corporate
View HTML
Toggle Summary OvaScience to Host Fourth Quarter and Fiscal Year 2016 Financial Results Conference Call
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 23, 2017-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.m.
View HTML
Toggle Summary OvaScience to Present at the 35th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 5, 2017-- OvaScience℠ (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that Michelle Dipp , M.D., Ph.D., Executive Chair and Co-founder of OvaScience , will present
View HTML
Toggle Summary OvaScience Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 23, 2016-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced the grant of inducement awards to purchase an aggregate of 356,000 shares of its common stock to
View HTML
Toggle Summary OvaScience Announces Business Update
– Maintaining AUGMENT Commercial Footprint; Increasing Focus on OvaPrime and OvaTure – – Improving Cost Structure Through Corporate Restructuring; Extending Cash Runway to Q1 2019 – – Chief Executive Officer Harald Stock , Ph.D., Hired to Lead Commercial Expansion, Stepping Down – WALTHAM, Mass.
View HTML
Toggle Summary OvaScience Reports Third Quarter 2016 Financial Results
– Broadened Patient Access to AUGMENT with New Clinic Agreements in Canada and Japan – – Expanded AUGMENT Clinical Program with Institutional Review Board (IRB) Approval for Company-Sponsored, Multi-Center Trial – – Conference Call Today at 4:30 p.m. ET – WALTHAM, Mass. --(BUSINESS WIRE)--Nov.
View HTML
Toggle Summary OvaScience to Present at the 25th Annual Credit Suisse Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 31, 2016-- OvaScience℠ (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that Harald Stock , Ph.D., President and Chief Executive Officer, will present a corporate
View HTML
Toggle Summary OvaScience to Host Third Quarter 2016 Financial Results Conference Call
WALTHAM, Mass. --(BUSINESS WIRE)--Oct. 27, 2016-- OvaScience SM  (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.m.
View HTML
Toggle Summary OvaScience Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Sep. 14, 2016-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the grant of an inducement awards to its newly appointed Chief Financial Officer,
View HTML
Toggle Summary OvaScience Announces Executive Management Changes and Appointments to Further Drive Company’s Growth
— Christophe Couturier Named Chief Financial Officer — — Karen Long Named Executive Vice President, Clinical and Regulatory Affairs and Quality Assurance — — James Luterman , Ph.D. Promoted to Executive Vice President, Research and Development — WALTHAM, Mass. --(BUSINESS WIRE)--Sep.
View HTML
Toggle Summary OvaScience to Present at Upcoming Investor Conferences in September
WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 31, 2016-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that Harald Stock , Ph.D., President and Chief Executive Officer, will present a corporate
View HTML
Toggle Summary OvaScience’s AUGMENT Treatment Commercially Available in Japan Through Partnership with IVF JAPAN GROUP
— Japan Represents Large and Growing Infertility Market with More than 365,000 IVF Cycles Annually 1 — WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 29, 2016-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options,
View HTML
Toggle Summary OvaScience Reports Second Quarter 2016 Financial Results
— AUGMENT revenues increased 30% in 2Q16 compared to 1Q16 — — Strong financial position enables execution of corporate strategy — — Conference call today at 4:30 p.m. ET — WALTHAM, Mass. --(BUSINESS WIRE)--Aug. 4, 2016-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the
View HTML
Toggle Summary OvaScience to Host Second Quarter 2016 Financial Results Conference Call
WALTHAM, Mass. --(BUSINESS WIRE)--Jul. 28, 2016-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.m.
View HTML
Toggle Summary Harald Stock, Ph.D. Commences Role as President and Chief Executive Officer of OvaScience
— Begins Role with Strategic Focus on Accelerating Access in Key Markets; Increasing Patient Engagement; and Building Additional Real World Data — WALTHAM, Mass.--( BUSINESS WIRE )--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization
View HTML
Toggle Summary OvaScience to Present at the JMP Securities Life Sciences Conference
WALTHAM, Mass.--(BUSINESS WIRE)--`OvaScience SM ( OVAS ), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that Company management will present at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016 at
View HTML
Toggle Summary OvaScience Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 3, 2016-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the grant of an inducement award to its newly appointed Executive Vice President, Human
View HTML
Toggle Summary OvaScience Announces Closing of Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)--Jun. 1, 2016-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the closing of its previously announced public offering, including the exercise in full by
View HTML
Toggle Summary OvaScience Announces Pricing of Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)--May 26, 2016-- OvaScience SM  (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it has priced its previously announced underwritten public offering of 7,150,000
View HTML
Toggle Summary OvaScience Announces Proposed Public Offering of Common Stock
WALTHAM, Mass. --(BUSINESS WIRE)--May 25, 2016-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it has commenced an underwritten public offering of shares of its common stock.
View HTML
Toggle Summary OvaScience Reports First Quarter 2016 Financial Results
— AUGMENT treatment gains traction in growing fertility market and Company expands access internationally — — New research supports AUGMENT and pipeline treatments— WALTHAM, Mass. --(BUSINESS WIRE)--May 5, 2016-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery,
View HTML
Toggle Summary OvaScience to Host First Quarter 2016 Financial Results Conference Call
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 28, 2016-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.m.
View HTML
Toggle Summary OvaScience Announces Senior Management Changes and Appointments
– Arthur Tzianabos , Ph.D., Departs as President and Chief Scientific Officer; James D. Luterman , Ph.D., Appointed Senior Vice President, Research & Development – WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 31, 2016-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery,
View HTML
Toggle Summary OvaScience Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 9, 2016-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today the grant of inducement awards to its newly appointed Chief Operating Officer, Paul Chapman
View HTML
Toggle Summary OvaScience to Present at Cowen and Company Health Care Conference
WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 7, 2016-- OvaScience SM (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that Company management will present at the Cowen and Company 36 th Annual Health Care
View HTML
Toggle Summary OvaScience Reports Fourth Quarter and Year-End 2015 Financial Results
— Harald Stock, Ph.D., Appointed as CEO-Elect, Paul Chapman Appointed as COO to Expand Global Commercial and Operational Expertise — — Egg Allocation Study Commenced in Spain — — Access to the AUGMENT SM Treatment Expanded to Japan — — In 2016 OvaScience Will Continue to Build Global Infrastructure
View HTML
Toggle Summary OvaScience Appoints Paul W.D. Chapman to Chief Operating Officer
– Industry Veteran Brings Proven Commercial and Operational Expertise to Executive Leadership Team – WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 25, 2016-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today
View HTML
Toggle Summary OvaScience to Host Fourth Quarter and Fiscal Year 2015 Financial Results Conference Call
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 18, 2016-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that it will host a conference call at 4:30 p.m.
View HTML
Toggle Summary OvaScience to Present at Leerink Global Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)--Feb. 3, 2016-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that Company management will present at the Leerink Partners 5th Annual Global Healthcare
View HTML
Toggle Summary OvaScience Announces 2016 Corporate Goals for Its Core Fertility Treatments
- Company Will Webcast New Presentation at 34th Annual J.P. Morgan Healthcare Conference - WALTHAM, Mass. --(BUSINESS WIRE)--Jan. 11, 2016-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new fertility treatment options, today
View HTML
Toggle Summary OvaScience Names Harald F. Stock Chief Executive Officer-Elect
- Industry Veteran Brings Proven, Global Commercial Expertise – – Michelle Dipp Appointed Executive Chairman of the Board of Directors – WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new
View HTML
Toggle Summary OvaScience’s AUGMENT Fertility Treatment Available in Japan
- IVF JAPAN Begins Preceptorship Program with AUGMENT Treatment - WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 14, 2015-- OvaScience SM (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the AUGMENT SM fertility
View HTML
Toggle Summary OvaScience to Present at the Oppenheimer Healthcare Conference
WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 7, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that Company management will present at the Oppenheimer 26 th Annual Healthcare Conference
View HTML
Toggle Summary OvaScience Provides Business Update and Outlines 2015 Corporate Progress
- Company Achieves 2015 OvaPrime and OvaTure Treatment Goals - WALTHAM, Mass. --(BUSINESS WIRE)--Dec. 7, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced the Company has achieved its
View HTML
Toggle Summary OvaScience Reports Third Quarter 2015 Financial Results
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 5, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported third quarter 2015 financial results and highlighted recent accomplishments.
View HTML
Toggle Summary OvaScience Provides Update on Corporate Goal for AUGMENT Treatment
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 28, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today announced that the Company does not expect to meet the 2015 goal of 1,000 AUGMENT SM treatment
View HTML
Toggle Summary OvaScience to Present at the Rodman & Renshaw/H.C. Wainwright Annual Global Investment Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 2, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that Company management will present at the Rodman & Renshaw 17 th Annual Global
View HTML
Toggle Summary Publication of OvaScience’s AUGMENT Fertility Treatment Shows Statistically Significant Improvements in Embryo Selection and Transfer Compared to Standard IVF
Real-World Experience from International IVF Clinics Reported in Peer-Reviewed Journal CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 26, 2015-- OvaScience SM (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today
View HTML
Toggle Summary Improved Pregnancy Rates and Healthy Births with OvaScience’s AUGMENT Fertility Treatment to be Published in Peer-Reviewed Journal
- New Analysis Shows Statistically Significant Higher Rates of Ongoing Pregnancies when Eggs from the Same Woman are Treated with AUGMENT Treatment versus Standard IVF Alone - - Higher Rate of Embryo Transfer with AUGMENT Treatment Based on Standard Embryo Quality Measures - - Company to Hold
View HTML
Toggle Summary OvaScience Reports Second Quarter 2015 Financial Results
- Healthy Babies Born with AUGMENT Fertility Treatment; IVF Clinics in New International Regions Offer AUGMENT Treatment - - 2015 Plans for OvaPrime and OvaTure Treatments on Track - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 10, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused
View HTML
Toggle Summary OvaScience Expands AUGMENT℠ Fertility Treatment Offering through IVI Group, the Largest IVF Clinic Network in the World
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 6, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that the AUGMENT SM fertility treatment will be introduced to patients at IVI Valencia, a
View HTML
Toggle Summary OvaScience to Present at the Wedbush PacGrow Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 5, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that Company management will present at the 2015 Wedbush PacGrow Healthcare Conference on
View HTML
Toggle Summary OvaScience to Present at the JMP Securities Life Sciences Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 18, 2015-- OvaScience℠ (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that Company management will present at the JMP Securities Life Sciences Conference on
View HTML
Toggle Summary OvaScience’s AUGMENT Treatment Shows Improved Pregnancy Rates and Live Births in Women with Poor Prognoses as Reported by Physicians During Annual International Fertility Meeting
- Additional Baby Born with AUGMENT Treatment - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 17, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced that physicians continue to report
View HTML
Toggle Summary OvaScience Expands Senior Team with Two New Key Hires
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 5, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today two new positions that support OvaScience’s expanding international operations.
View HTML
Toggle Summary OvaScience Welcomes John Howe, M.D., Former President and CEO of Project HOPE, to Board of Directors
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 5, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today the appointment of John P. Howe, III , M.D., former President and Chief Executive Officer
View HTML
Toggle Summary OvaScience to Present at the Jefferies 2015 Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 26, 2015-- OvaScience SM (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that Company management will present at the Jefferies 2015 Healthcare Conference on
View HTML
Toggle Summary OvaScience Announces Ravi Mehrotra, Ph.D., Joins as Chief Corporate Development Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 18, 2015-- OvaScience SM (NASDAQ:OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that Ravi Mehrotra , Ph.D., has joined the Company as Chief Corporate Development Officer.
View HTML
Toggle Summary OvaScience’s AUGMENT Fertility Treatment Continues to Demonstrate Improved Pregnancy Rates in Women with Very Poor Prognoses
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 15, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today additional clinical experience with the Company’s AUGMENT SM fertility treatment, showing
View HTML
Toggle Summary OvaScience Reports First Quarter 2015 Financial Results
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 11, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported first quarter 2015 financial results and highlighted recent accomplishments.
View HTML
Toggle Summary First Baby Born with OvaScience’s AUGMENT Fertility Treatment
- Innovative Fertility Treatment Developed to Improve Egg Health , a Major Factor in IVF Success - CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 7, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options,
View HTML
Toggle Summary OvaScience Welcomes John Sexton, President of New York University, to Board of Directors
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 30, 2015-- OvaScience℠ (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today the appointment of John E. Sexton , Ph.D., President of New York University ( NYU ), to
View HTML
Toggle Summary Additional Clinical Reports of OvaScience AUGMENT Fertility Treatment Show Improved Pregnancy Rates in Women with Multiple Prior Failed IVF Cycles
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 28, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that additional clinical experience of the Company’s AUGMENT SM treatment demonstrated
View HTML
Toggle Summary OvaScience AUGMENT Fertility Treatment Shows Improved Pregnancy Rates in Women with Prior Failed IVF Cycles
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 26, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that presentations by fertility specialists offering the Company’s AUGMENT SM fertility
View HTML
Toggle Summary OvaScience to Host Conference Call and Webcast Presentation with IVF Specialists to Review Early AUGMENT Fertility Treatment Patient Experience
Overview of AUGMENT Presentation at Society for Reproductive Investigation Meeting and Select Patient Case Studies CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 25, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new
View HTML
Toggle Summary AUGMENT Fertility Treatment to be Highlighted at Society for Reproductive Investigation (SRI) Annual Meeting
First Clinical Experience Presentations to Include Initial Pregnancy Data CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 17, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, announced today that in vitro
View HTML
Toggle Summary OvaScience CEO Michelle Dipp Elected as Young Global Leader by World Economic Forum
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 17, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, is pleased to announce that Michelle Dipp , M.D., Ph.D., was elected to join the World Economic Forum’s
View HTML
Toggle Summary OvaScience Reports Fourth Quarter and Year End 2014 Financial Results
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 16, 2015-- OvaScience SM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported fourth quarter and year end 2014 financial results and highlighted recent
View HTML
Toggle Summary OvaScience to Participate in Credit Suisse Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 26, 2015-- OvaScience SM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Company management will participate in the Credit Suisse Global Healthcare
View HTML
Toggle Summary OvaScience to Present at Leerink Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 4, 2015-- OvaScience SM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Company management will present at the Leerink Global Healthcare Conference
View HTML
Toggle Summary OvaScience Announces Closing of $132 Million Public Offering of Common Stock including Exercise of Underwriters’ Option to Purchase Additional Shares
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 13, 2015-- OvaScience SM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today the closing of its previously announced public offering of common stock,
View HTML
Toggle Summary OvaScience to Present at the J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 9, 2015-- OvaScience SM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Michelle Dipp , M.D., Ph.D., Chief Executive Officer of OvaScience , will
View HTML
Toggle Summary OvaScience Prices $115 Million Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 7, 2015-- OvaScience SM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that it has priced its previously announced underwritten public offering of
View HTML
Toggle Summary OvaScience Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 6, 2015-- OvaScience SM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today it has commenced an underwritten public offering of up to $85 million of shares of
View HTML
Toggle Summary OvaScience Advances All Three Fertility Treatment Options
- AUGMENT Treatment Available in Four International Regions - - OvaPrime Treatment to be Introduced into Select International IVF Clinics by the End of 2015 - - OvaTure Treatment, a Potential Hormone-Free Fertility Option, Progresses into Development - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec.
View HTML
Toggle Summary OvaScience to Host Investor Day
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 12, 2014-- OvaScience SM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that the Company is hosting an Investor Day on Wednesday, December 17, 2014 at
View HTML
Toggle Summary OvaScience Strengthens Management Team to Support Expanding Global Operations
- Promotes Arthur Tzianabos, Ph.D., to President; Appoints New Head of Commercial - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 11, 2014-- OvaScience SM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced
View HTML
Toggle Summary OvaScience to Present at the Oppenheimer Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 4, 2014-- OvaScience SM (NASDAQ:OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Company management will present at the Oppenheimer 25 th Annual Healthcare
View HTML
Toggle Summary OvaScience to Participate in Fortune Most Powerful Women Next Gen Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 26, 2014-- OvaScience SM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Michelle Dipp , M.D., Ph.D., Chief Executive Officer of OvaScience , will
View HTML
Toggle Summary OvaScience to Participate in Partnering for Cures Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 11, 2014-- OvaScience SM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Company management will participate in the Partnering for Cures meeting, an
View HTML
Toggle Summary OvaScience Reports Third Quarter 2014 Financial Results
- Company Ahead of Schedule in Achieving Key 2014 AUGMENT SM Treatment Goal - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 10, 2014-- OvaScience SM (NASDAQ:OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today reported third
View HTML
Toggle Summary OvaScience CEO Michelle Dipp Named Outstanding Young Leader
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 18, 2014-- OvaScience SM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today Michelle Dipp , M.D, Ph.D., Chief Executive Officer at OvaScience , has received
View HTML
Toggle Summary OvaScience Appoints Jeffrey Young to Chief Financial Officer
- Reports Inducement Option Grant under NASDAQ Rule 5635(c)(4) - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 18, 2014-- OvaScience SM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today the appointment
View HTML
Toggle Summary OvaScience to Present at the Rodman & Renshaw/H.C. Wainwright Annual Global Investment Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 3, 2014-- OvaScience℠ (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Company management will present at the Rodman & Renshaw 16 th Annual Global
View HTML
Toggle Summary OvaScience Reports Second Quarter 2014 Financial Results
- AUGMENT℠ Treatment Available in Three International Regions; Company More than Halfway Toward Goal of 40 AUGMENT Cycles in 2014 - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 7, 2014-- OvaScience SM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and
View HTML
Toggle Summary OvaScience to Present at the Wedbush Life Sciences Management Access Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 6, 2014-- OvaScience SM (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Company management will present at the Wedbush Securities Life Sciences
View HTML
Toggle Summary OvaScience to Present at the 2014 BIO International Convention
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 23, 2014-- OvaScience SM , (NASDAQ:OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Michelle Dipp , M.D., Ph.D., Chief Executive Officer of OvaScience , will
View HTML
Toggle Summary OvaScience to Present at the JMP Securities Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 18, 2014-- OvaScience SM , (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Arthur Tzianabos , Ph.D., Chief Scientific Officer of OvaScience , will
View HTML
Toggle Summary OvaScience to Present at the Jefferies 2014 Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 27, 2014-- OvaScience SM , (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that the Company's management team will present at the Jefferies 2014 Global
View HTML
Toggle Summary OvaScience Reports First Quarter 2014 Financial Results
-- Company Commenced International Launch of AUGMENT SM -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 8, 2014-- OvaScience SM , (NASDAQ:OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today reported first quarter 2014
View HTML
Toggle Summary OvaScience to Present at the 39th Annual Deutsche Bank Health Care Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 1, 2014-- OvaScience SM , (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that Michelle Dipp , M.D., Ph.D., Chief Executive of OvaScience , will present at
View HTML
Toggle Summary OvaScience Co-Founder David Sinclair, Ph.D., Selected by TIME as one of the 100 Most Influential People in The World
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 24, 2014-- OvaScience SM , (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today announced that the Company’s scientific Co-Founder,  David Sinclair , Ph.D., has been
View HTML
Toggle Summary OvaScience Announces Exercise of Over-Allotment Option in Public Offering of Common Stock
-- Company Management and Directors Establish Stock Purchase Plans -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 18, 2014-- OvaScience SM , (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today that the
View HTML
Toggle Summary OvaScience to Present at the 26th Annual ROTH Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 6, 2014-- OvaScience SM , (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of female fertility treatments, today announced that Michelle Dipp , M.D., Ph.D., Chief Executive Officer of OvaScience will
View HTML
Toggle Summary OvaScience Prices $50 Million Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 4, 2014-- OvaScience SM , (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced the pricing of $10.00 per share for its previously announced underwritten public
View HTML
Toggle Summary OvaScience Announces Proposed Public Offering of Common Stock
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 3, 2014-- OvaScience SM , (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, announced today it has commenced an underwritten public offering of shares of its common stock.
View HTML
Toggle Summary OvaScience Reports Fourth Quarter and Year End 2013 Financial Results
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 27, 2014-- OvaScience SM , (NASDAQ: OVAS), a global life sciences company focused on the discovery, development and commercialization of new fertility treatments, today reported fourth quarter and year end 2013 financial results, and highlighted recent
View HTML
Toggle Summary OvaScience Issued Two U.S. Patents Covering AUGMENT℠ Fertility Treatment
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 12, 2014-- OvaScience SM (NASDAQ:OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, today announced the issuance of two United States patents covering its AUGMENT SM fertility treatment.
View HTML
Toggle Summary OvaScience Appoints Fertility Pioneer Jamie Grifo M.D., Ph.D., to Clinical Advisory Board
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 4, 2014-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, announced today the appointment of Jamie Grifo , M.D., Ph.D., of the New York University ( NYU )
View HTML
Toggle Summary OvaScience to Present at Upcoming Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb. 3, 2014-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, today announced that the Company's management team will present at two upcoming conferences in
View HTML
Toggle Summary OvaScience Provides Update on Pipeline Advancements and Commercial Plans; New Potential Fertility Treatment OvaPrime℠ to Launch in 2015
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 13, 2014-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of female fertility treatments, today provided an update on its product pipeline and commercial plans, which are based on its egg
View HTML
Toggle Summary OvaScience Announces Global Healthcare Strategist Marc Kozin Joins Company’s Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 10, 2014-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appointment of Marc Kozin , former President of L.E.K.
View HTML
Toggle Summary OvaScience Appoints David Stern to Executive Vice President, Global Commercial Operations
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 9, 2014-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appointment of David Stern to the position of Executive Vice President, Global
View HTML
Toggle Summary OvaScience’s EggPC Technology Recognized by Science as a Top Ten Advancement in Reproductive Medicine
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 8, 2014-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Science magazine has named OvaScience's egg precursor cell (EggPC SM )
View HTML
Toggle Summary OvaScience to Present at the 2014 J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 7, 2014-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Michelle Dipp , M.D., Ph.D., Chief Executive Officer of OvaScience , will
View HTML
Toggle Summary OvaScience and Intrexon Collaborate to Accelerate Development of OvaScience’s OvaTure℠ Technology for Infertility Treatments
Companies also Form Joint Venture to Develop Applications to Prevent Inherited Human Diseases and Improve Animal Health CAMBRIDGE, Mass. & GERMANTOWN, Md. --(BUSINESS WIRE)--Dec. 19, 2013-- OvaScience , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and
View HTML
Toggle Summary OvaScience CEO Michelle Dipp, M.D., Ph.D., Joins Biotechnology Industry Organization’s Board of Directors
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 9, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appointment of Michelle Dipp , M.D., Ph.D., Chief Executive Officer of
View HTML
Toggle Summary OvaScience to Present at the Oppenheimer 2013 Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec. 6, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Michelle Dipp , M.D., Ph.D., Chief Executive Officer of OvaScience , will
View HTML
Toggle Summary OvaScience Among 50 on Fire Finalists for Innovation Across All Industries in Boston
- Company received 2012 award for innovation in healthcare and medicine - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 5, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that
View HTML
Toggle Summary OvaScience to Participate in Therapeutic Area Partnerships (TAP) Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 18, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Michelle Dipp , M.D., Ph.D., Chief Executive Officer of OvaScience will
View HTML
Toggle Summary OvaScience Reports Third Quarter Fiscal 2013 Financial Results
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 13, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today reported financial results for the quarter ended September 30, 2013 , as well as recent
View HTML
Toggle Summary OvaScience Advisor Receives the American Fertility Association’s Visionary Award
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 4, 2013-- OvaScience SM , (NASDAQ:OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Clinical Advisory Board member Alan Penzias , M.D., has been honored by The
View HTML
Toggle Summary OvaScience Featured at RESOLVE New England Annual Fertility Conference
-- First baby born through in vitro fertilization in U.S. to present keynote -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 1, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today
View HTML
Toggle Summary OvaScience Appoints Hugh Taylor, M.D., to Scientific Advisory Board
- Company establishes research agreement with Dr. Taylor and his team at the Yale School of Medicine to study endometriosis, a major cause of female infertility - CAMBRIDGE, Mass. --(BUSINESS WIRE)--Oct. 24, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery,
View HTML
Toggle Summary OvaScience to Present at CareFWD 2013 Conference Exploring Healthcare Innovations
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Oct. 1, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Michelle Dipp , M.D., Ph.D., Chief Executive Officer of OvaScience will
View HTML
Toggle Summary OvaScience Reports Inducement Option Grant under NASDAQ Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 20, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today announced, as required under NASDAQ Listing Rule 5635(c)(4), that the Company has approved
View HTML
Toggle Summary OvaScience Chief Executive Officer Establishes Stock Purchase Plan
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 18, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Michelle Dipp , M.D., Ph.D., Chief Executive Officer of OvaScience , has
View HTML
Toggle Summary OvaScience Provides Update on AUGMENT℠
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 10, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today provided a regulatory, manufacturing and international strategy update on AUGMENT, the
View HTML
Toggle Summary OvaScience to Present at the Stifel Nicolaus 2013 Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 6, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that the Company’s management team will present at the Stifel Nicolaus 2013
View HTML
Toggle Summary OvaScience to Ring the NASDAQ Stock Market Opening Bell
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Sep. 3, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Michelle Dipp , M.D., Ph.D., Chief Executive Officer of OvaScience , will
View HTML
Toggle Summary OvaScience Reports Second Quarter Fiscal 2013 Financial Results
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 13, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today reported financial results for the quarter ended June 30, 2013 , and highlighted the
View HTML
Toggle Summary OvaScience to Present at 2013 Wedbush Securities Life Sciences Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 7, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Michelle Dipp , M.D., Ph.D., Chief Executive Officer of OvaScience will
View HTML
Toggle Summary OvaScience Appoints Arthur Tzianabos, Ph.D., to Chief Scientific Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 30, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appointment of Arthur Tzianabos , Ph.D., to the position of Chief Scientific
View HTML
Toggle Summary OvaScience Announces Creation of International Product Advisory Board
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 8, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the creation of an International Product Advisory Board (IPAB).
View HTML
Toggle Summary OvaScience to Present at 2013 JMP Securities Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 3, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that OvaScience management will present at the 2013 JMP Securities Healthcare on
View HTML
Toggle Summary OvaScience Added To Russell 2000® Index
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jul. 1, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that the Company has been added to the Russell 2000 ® Index.
View HTML
Toggle Summary OvaScience to Present at Conference on Bioinnovation at the MIT Media Lab
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 28, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today announced that Michelle Dipp , M.D., Ph.D., Chief Executive Officer of
View HTML
Toggle Summary OvaScience Appoints Mary Fisher to Company’s Board of Directors
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 11, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appointment of Mary Fisher , President and Chief Executive Officer of
View HTML
Toggle Summary OvaScience Co-Founders’ Review of Female Infertility Published in Cell Metabolism
-- Findings Highlight that Egg Quality Decreases With Age Due to Reduced Mitochondrial Function -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 4, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for
View HTML
Toggle Summary OvaScience Chief Executive Officer Selected Entrepreneur of The Year 2013 Finalist for New England by Ernst & Young
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 3, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Michelle Dipp , M.D., Ph.D., fertility advocate, co-founder and Chief
View HTML
Toggle Summary OvaScience to Present at Jefferies 2013 Global Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May. 29, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today announced that Michelle Dipp , M.D., Ph.D., Chief Executive Officer of OvaScience , will
View HTML
Toggle Summary OvaScience Technology Featured at the Society for Gynecologic Investigation Summit
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May. 28, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today announced that the Company’s egg precursor cell (EggPC SM ) technology platform will be
View HTML
Toggle Summary OvaScience Publishes Article Highlighting the Role of Mitochondria in Improving Fertility Outcomes
Company’s technology is translating mitochondrial science into potential new fertility treatment options CAMBRIDGE, Mass. --(BUSINESS WIRE)--May. 21, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for
View HTML
Toggle Summary OvaScience Co-Founder Recognized in Boston Globe 100’s “The Innovators” Feature
Company also named among Boston’s 50 on Fire CAMBRIDGE, Mass. --(BUSINESS WIRE)--May. 20, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today announced that OvaScience Co-Founder Jonathan
View HTML
Toggle Summary OvaScience to Present at Upcoming Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May. 16, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today announced that the Company's management team will present at two upcoming conferences in
View HTML
Toggle Summary OvaScience Reports First Quarter Fiscal 2013 Financial Results
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May. 15, 2013-- OvaScience SM , (NASDAQ: OVAS), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today reported financial results for the quarter ended March 31, 2013 , and highlighted the
View HTML
Toggle Summary OvaScience Announces Listing on NASDAQ Under Ticker Symbol “OVAS”
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 25, 2013-- OvaScience SM , (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today announced that the Company’s common stock that currently trades on the Over-the-Counter
View HTML
Toggle Summary OvaScience to Participate in Panel Featuring Innovative Companies at Greater Boston Chamber of Commerce Women’s Network Breakfast
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Apr. 25, 2013-- OvaScience SM , (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced that Michelle Dipp , M.D., Ph.D., Chief Executive Officer of OvaScience , will be a
View HTML
Toggle Summary OvaScience to Present at 25th Annual ROTH Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 14, 2013-- OvaScience SM , (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today announced that Michelle Dipp , M.D., Ph.D., Chief Executive Officer of OvaScience , will
View HTML
Toggle Summary OvaScience Announces Agreement for $35 Million Private Placement
BOSTON --(BUSINESS WIRE)--Mar. 13, 2013-- OvaScience SM , (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today announced the execution of a securities purchase agreement with certain institutional and accredited
View HTML
Toggle Summary OvaScience Infertility Technology Featured at 15th World Congress on Human Reproduction
-- Congressional Lecture and Oral Presentation on OvaScience’s Novel EggPC Technology -- CAMBRIDGE, Mass. --(BUSINESS WIRE)--Mar. 12, 2013-- OvaScience SM , (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today
View HTML
Toggle Summary OvaScience to Present at Cowen and Company 33rd Annual Health Care Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 28, 2013-- OvaScience SM , (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today announced that Michelle Dipp , M.D., Ph.D., Chief Executive Officer of OvaScience , will
View HTML
Toggle Summary OvaScience Presents Potential New Approach to Addressing Infertility at New York Society of Reproductive Medicine Meeting
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 27, 2013-- OvaScience SM , (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today announced that Co-Founder Jonathan L. Tilly , Ph.D., and Chief Executive Officer and
View HTML
Toggle Summary OvaScience Reports Fourth Quarter and Year-End 2012 Financial Results
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 25, 2013-- OvaScience SM , (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today reported fourth quarter and full year 2012 financial results, and highlighted key
View HTML
Toggle Summary OvaScience Appoints Harald Stock to Board of Directors
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 8, 2013-- OvaScience SM , (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appointment of Harald F. Stock , Ph.D., Chief Executive Officer of the
View HTML
Toggle Summary OvaScience to Present at Upcoming Conferences
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 29, 2013-- OvaScience SM , (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Michelle Dipp , M.D., Ph.D., Chief Executive Officer of OvaScience , will
View HTML
Toggle Summary OvaScience to Present at the 31st Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 3, 2013-- OvaScience SM , (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Michelle Dipp , M.D., Ph.D., Chief Executive Officer of OvaScience , will
View HTML
Toggle Summary OvaScience Appoints Alison Lawton to Chief Operating Officer
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 2, 2013-- OvaScience SM , (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today the appointment of Alison Lawton to Chief Operating Officer.
View HTML
Toggle Summary Women may make new eggs View HTML
Toggle Summary OvaScience to Present at the Oppenheimer Annual Healthcare Conference
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Dec. 7, 2012-- OvaScience SM , (OTC: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Michelle Dipp , M.D., Ph.D., Chief Executive Officer of OvaScience , will
View HTML
Toggle Summary OvaScience Announces Third Quarter Fiscal 2012 Financial Results
OvaScience Announces Third Quarter Fiscal 2012 Financial Results | Business Wire CAMBRIDGE, Mass.--( BUSINESS WIRE )-- OvaScience SM , (OTCBB: OVSC), a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, today reported financial
View HTML
Toggle Summary OvaScience to Present at the Lazard 2012 Healthcare Conference
CAMBRIDGE, Mass. – November 12, 2012 – OvaScience, a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Michelle Dipp, M.D., Ph.D., Chief Executive Officer of OvaScience, will present at the Lazard Capital
View HTML
Toggle Summary OvaScience Announces Listing on OTCBB and OTC LINK
CAMBRIDGE, Mass. – November 9, 2012 – OvaScience, a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that its common stock has been approved for quotation on the OTC Bulletin Board (OTCBB) and the OTC Market Group's
View HTML
Toggle Summary OvaScience Appoints Thomas Malley to Board of Directors
CAMBRIDGE, Mass. October 31, 2012 - OvaScience, a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced the appointment of Thomas Malley to its Board of Directors. “Tom’s knowledge of the healthcare industry and his expertise
View HTML
Toggle Summary OvaScience to Host Scientific Symposium at 2012 American Society of Reproductive Medicine Annual Meeting
CAMBRIDGE, Mass. October 18, 2012 - OvaScience, a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that it will be attending and hosting a scientific symposium during the 68th Annual Meeting of the American Society
View HTML
Toggle Summary Michelle Dipp, 36, reflects biotech’s next generation View HTML
Toggle Summary OvaScience to Present at Upcoming 2012 Investor Conferences
CAMBRIDGE, Mass. September 7, 2012 - OvaScience, a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Michelle Dipp, M.D., Ph.D., chief executive officer of OvaScience, will present at two upcoming investor
View HTML
Toggle Summary OvaScience to Present at the Stifel Nicolaus 2012 Healthcare Conference
CAMBRIDGE, Mass. September 4, 2012 - OvaScience, a life sciences company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Michelle Dipp, M.D., Ph.D., chief executive officer of OvaScience, will present at the Stifel Nicolaus 2012
View HTML
Toggle Summary OvaScience to Present at the Boston CEO Conference
CAMBRIDGE, Mass., Jun 07, 2012 -- OvaScience™, a fertility company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Michelle Dipp, M.D., Ph.D., chief executive officer of OvaScience, will present at the Boston CEO 2012 Conference on
View HTML
Toggle Summary OvaScience to Present at Jefferies 2012 Global Healthcare Conference
BOSTON, Mass., May 31, 2012 – OvaScience™, a fertility company focused on the discovery, development and commercialization of new treatments for infertility, announced today that Michelle Dipp, M.D., Ph.D., chief executive officer of OvaScience, will present at the Jefferies 2012 Global Healthcare
View HTML
Toggle Summary Editor's Corner: "EmbryoSpeak": A New Kind of IVF, The Journal of Clinical Embryology
To read more visit: The Journal of Clinical Embryology
View HTML
Toggle Summary Egg Stem Cells, Technology Review published by MIT
To read more visit: http://www.technologyreview.com/article/40241/
View HTML
Toggle Summary OvaScience to Present at Boston Biotech Business Development Conference
CAMBRIDGE, Mass., April 10, 2012 – OvaScience™, a fertility company focused on the discovery, development and commercialization of novel treatments for infertility, announced today that the company will present at the 2012 Boston Biotech Business Development Conference, being held April 17-18 at
View HTML
Toggle Summary OvaScience Secures $37 Million in Series B Financing
CAMBRIDGE, Mass., April 4, 2012 – OvaScience™, a fertility company focused on the discovery, development and commercialization of novel treatments for infertility, today announced that it has completed a $37 million Series B financing. The financing was led by General Catalyst.
View HTML
Toggle Summary OvaScience Appoints Jeffrey D. Capello to Board of Directors
BOSTON, Mass., April 3, 2012 – OvaScience™, an innovative life science company dedicated to improving the treatment of infertility, today announced the appointment of Jeffrey D. Capello, executive vice president and chief financial officer of Boston Scientific (NYSE: BSX), to its board of
View HTML
Toggle Summary OvaScience to Present at Shanghai CEO Conference
BOSTON, Mar 22, 2012 (BUSINESS WIRE) -- OvaScience™, a fertility company focused on the discovery, development and commercialization of novel treatments for infertility, announced today that Michelle Dipp, M.D., Ph.D., chief executive officer of OvaScience, will present at the Shanghai CEO
View HTML
Toggle Summary OvaScience to Present at Cowen and Company’s 32nd Annual Health Care Conference
BOSTON, Mass., March 5, 2012 – OvaScience™, a fertility company focused on the discovery, development and commercialization of novel treatments for infertility, announced today that Michelle Dipp, M.D., Ph.D., chief executive officer of OvaScience, will present at the Cowen and Company 32nd Annual
View HTML
Toggle Summary OvaScience SAB member, Alan Penzias, M.D., named to WHO Infertility Global Guidelines and Research Group
OvaScience SAB member, Alan Penzias, M.D., named to WHO Infertility Global Guidelines and Research Group
View HTML
Toggle Summary Nature Medicine Study Demonstrates Eggs Can Mature From a Woman’s Own Egg Precursor Cells
OvaScience Co-Founder, Dr. Jonathan Tilly, Confirms Potential New Treatment Paradigm for Infertility BOSTON, Mass., February 27, 2012 - OvaScience™, a fertility company focused on the discovery, development and commercialization of novel treatments for infertility, today announced the publication
View HTML
Toggle Summary OvaScience to Present at the Leerink Swann 2012 Global Healthcare Conference
BOSTON, Mass., February 13, 2012 – OvaScience™, an innovative life science company dedicated to improving the treatment of infertility, today announced that the company will present at the Leerink Swann 2012 Global Healthcare Conference, being held February 15-16 at The Waldorf Astoria Hotel in New
View HTML
Toggle Summary SAB Member, Dr. Alan Penzias, elected Vice Chair of the Board of Directors of The American Fertility Association
The American Fertility Association announced newly elected officers of their Board of Directors: http://www.sacbee.com/2012/01/30/4224756/the-american-fertility-association.html OvaScience SAB member, Dr. Alan Penzias , was elected Vice Chair.
View HTML
Toggle Summary Aging Eggs: Exciting Research Is on the Horizon, The Fertility Authority
To read the full article please visit: http://www.fertilityauthority.com
View HTML
Toggle Summary OvaScience a Team RESOLVE Partner in 2012
About RESOLVE: The National Infertility Association Founded in 1974, RESOLVE: The National Infertility Association, headquartered in McLean, VA, is the oldest and largest consumer-based, nonprofit group that provides education, advocacy and compassionate support for those struggling with
View HTML
Toggle Summary OvaScience SAB member, Alan Penzias, M.D., named to US News and World Report Top Doctors List for 2011
OvaScience SAB member, Alan Penzias, M.D., was named one of the top 15 Reproductive Endocrinologist in Massachusetts for 2011 by US News and World Report.
View HTML
Toggle Summary OvaScience to Present at Lazard Capital Markets 8th Annual Healthcare Conference
Michelle Dipp, CEO, to present at Lazard conference on Wednesday November 16th, 2011 BOSTON, Mass., Nov. 15, 2011 - OvaScience™, an innovative life science company dedicated to improving the treatment of infertility, today announced that the company has been invited to present at the Lazard Capital
View HTML
Toggle Summary SAB Members Presenting at ASRM 2011
OvaScience Scientific Advisory Board members to present at American Society for Reproductive Medicine (ASRM) 67th Annual Meeting. ASRM 2011 will be held Oct.15-19, 2011 at the Orange County Convention Center in Orlando, Fla. Kelle Moley, SAB member to present at ASRM symposium on 10/17: Nutrition,
View HTML
Toggle Summary OvaScience aims to improve odds of fertility procedure, Boston Globe
OvaScience aims to improve odds of fertility procedure
View HTML
Toggle Summary OvaScience Uses Stem Cells to Revive Fertility, Xconomy
To read more visit: http://www.xconomy.com
View HTML
Toggle Summary Fertility co. changes odds for conception, Boston Herald
To read more visit: http://www.bostonherald.com
View HTML